share_log

公告精选 | 融创中国:杭州西奥同意受让浙江启隆15.625%股权及债权;电视广播:将重组电视广播和电子商贸业务

Selected announcements | Sunac China: Hangzhou Xiao agreed to transfer 15.625% of Zhejiang Qilong's shares and bonds; TV broadcast: TV broadcasting and e-commerce business will be restructured

Futu News ·  Nov 28, 2023 08:17

Big announcement

1. Sunac China: Hangzhou Xiao agreed to transfer 15.625% of Zhejiang Qilong's shares and bonds

$SUNAC (01918.HK)$An announcement was issued. In order to clarify and resolve the existing debt issues of the Shanghai Yalong project to meet the prerequisites for Huarong loan cooperation, on November 27, 2023, Shanghai Haoxuan, Shanghai Sunac, and Hangzhou West signed an agreement. Hangzhou Xiao agreed to transfer 15.625% of Zhejiang Qilong's shares and claims through restructuring arrangements at a cost of about RMB 2.5 billion, of which approximately RMB 2.4 billion will be offset by existing debts and debts. The remaining RMB 100 million will be repaid by Hangzhou Xiao on Shanghai Haoxuan's debt to Xinhu Zhongbao.

2. TV broadcasting: TV broadcasting and e-commerce business will be reorganized

$TVB (00511.HK)$The announcement announced that in order to enhance audience and user experience, increase operational efficiency, and enhance long-term revenue potential, the Group will restructure its television broadcasting and e-commerce business.

3. Bosideng: Profit attributable to shareholders for the interim period in 2023 was 919 million yuan, up 25.1% year on year

$BOSIDENG (03998.HK)$According to the announcement, for the six months ended September 30, 2023, Bosideng's revenue increased by 20.9% to approximately RMB 7.472 billion. Operating profit increased 1.2 percentage points to 16.5%; profit attributable to equity shareholders of the company increased 25.1% to about $919 million; and the board of directors declared an interim dividend of 5 HK cents per common share.

4. China Education Holdings: Annual adjusted net profit increased 6.0% to 1.908 billion yuan

$CHINA EDU GROUP (00839.HK)$The results for the year ended August 31, 2023 were announced. The group obtained revenue of RMB 5.616 billion (same unit below), up 18.1% year on year; adjusted net profit of $2,077 billion, up 9.8% year on year; company owners accounted for adjusted net profit of $1,908 million, up 6% year on year; and proposed final dividend of 13.53 points per share.

Important matters

$TVB (00511.HK)$: TV broadcasting and e-commerce businesses will be restructured to optimize audience and user experience, improve operational efficiency and increase revenue potential

$SUNAC (01918.HK)$: Hangzhou Xiao agreed to transfer 15.625% of Zhejiang Qilong's shares and bonds

Earnings Report

$BOSIDENG (03998.HK)$Profit attributable to shareholders for the interim period of 2023 was 919 million yuan, up 25.1% year on year

$CHINA EDU GROUP (00839.HK)$Annual adjusted net profit increased 6.0% to 1.908 billion yuan with final interest of 13.53 points

$C VOCATIONAL ED (01756.HK)$Annual adjusted net profit of 405 million yuan increased 53.6% year-on-year

$MONGOLIA ENERGY (00276.HK)$Losses attributable to owners in the medium term narrowed to HK$547 million

$TIME INTERCON (01729.HK)$Interim profit of HK$151 million increased 65.7% year-on-year

Operational data

$BAY AREA DEV (00737.HK)$: The total toll revenue of the Guangzhou-Shenzhen Expressway in October was 223 million yuan, up 38% year on year

Pharmaceutical Innovation

$CSPC PHARMA (01093.HK)$: Highly selective SOS1 inhibitor (SYH2038) approved for clinical trials

$FOSUN PHARMA (02196.HK)$: A clinical trial application for injecting HLX43 to treat advanced/metastatic solid tumors was approved by the US FDA

$GRANDPHARMA (00512.HK)$: The global innovative product STC3141 China Phase II clinical study completed the first patient enrolled in group administration

$SINOMAB BIO-B (03681.HK)$: SM17 completed the administration of the first cohort of healthy subjects in the phase I clinical trial in China

$JENSCARE-B (09877.HK)$: Results of the first year of the LUX-Valve confirmatory clinical trial were presented at the 2023 London Valvular Heart Disease Interventional Treatment Conference

$ABBISKO-B (02256.HK)$: Pimicotinib (ABSK021) for the treatment of advanced pancreatic cancer phase II clinical trial completed administration of the first case in China

Repurchase cancellation

$TENCENT (00700.HK)$On November 27, 1.25 million shares were repurchased at a cost of HK$402 million

$AIA (01299.HK)$Repurchase of 1,910,800 shares at a cost of HK$135 million on November 27

$HSBC HOLDINGS (00005.HK)$Repurchase of 1,8912 million shares at a cost of HK$113 million on November 24

$KUAISHOU-W (01024.HK)$Repurchase of 1 million shares at a cost of HK$58.3 million on November 27

$SINOPEC CORP (00386.HK)$On November 27, 9.53 million shares were repurchased at a cost of HK$38.997 million

$COSCO SHIP HOLD (01919.HK)$Repurchase of 2,282,500 shares at a cost of HK$16.36 million on November 27

$JIUMAOJIU (09922.HK)$On November 27, 1,813,000 shares were repurchased at a cost of HK$1,515,800

Editor/Somer

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment